Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.34 USD
Change Today +0.0101 / 3.06%
Volume 15.8K
ULUR On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

uluru inc (ULUR) Snapshot

Open
$0.33
Previous Close
$0.33
Day High
$0.34
Day Low
$0.30
52 Week High
09/5/14 - $1.25
52 Week Low
08/24/15 - $0.24
Market Cap
8.4M
Average Volume 10 Days
24.7K
EPS TTM
$-0.11
Shares Outstanding
24.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ULURU INC (ULUR)

Related News

No related news articles were found.

uluru inc (ULUR) Related Businessweek News

No Related Businessweek News Found

uluru inc (ULUR) Details

ULURU Inc., a specialty pharmaceutical company, develops and commercializes a range of wound care and mucoadhesive film products in the United States and internationally. It develops its products based on patented Nanoflex and OraDisc drug delivery technologies. The company’s products include Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and abrasions, as well as non-healing surgical wounds, trauma, and chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers. It also offers Aphthasol for the treatment of canker sores, as well as for use in the prevention of formation of ulcers; OraDisc A for the treatment of oral conditions, which rely upon the use of medications formulated as gels and pastes that are applied to lesions in the mouth; and OraDisc B, a mucoadhesive disc product that is use for the treatment and management of oral pain. The company’s OraDisc products are also used for various dental applications. ULURU Inc. is based in Addison, Texas.

7 Employees
Last Reported Date: 05/20/15

uluru inc (ULUR) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $335.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $200.0K
Vice President of Polymer Drug Delivery
Total Annual Compensation: $175.0K
Compensation as of Fiscal Year 2014.

uluru inc (ULUR) Key Developments

ULURU Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

ULURU Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported a net loss of $729,000, or $0.03 per share, as compared with a net loss of $710,000, or $0.03 per share, for the same period last year. Revenues were $259,000, as compared to $209,000 for the second quarter of 2014. The net increase of approximately $50,000 in revenues is attributable to an increase in Altrazeal product sales of $67,000 to international distributors; which was partially offset by a decrease of $17,000 in royalties. Loss before income taxes was $729,379 compared to $729,379 a year ago. Operating loss was $701,337 compared to $677,512 a year ago. For the six months, the company’s net loss was $1.47 million, or $0.06 per share, as compared with a net loss of $1.58 million, or $0.07 per share, for the same period last year. Revenues were $554,000, as compared to $311,000 for the comparative period of 2014. The net increase of approximately $243,000 in revenues is attributable to an increase in Altrazeal product sales of $260,000 to international distributors; which was partially offset by a decrease of $17,000 in royalties from international distributors. Loss before income taxes was $1,467,652 compared to $1,578,006 a year ago. Operating loss was $1,334,005 compared to $1,450,957 a year ago.

Uluru Inc. Appoints Bradley J. Sacks to the Board of Directors

ULURU Inc. announced that in response to the nomination of two directors by a major stockholder, the company's Board of Directors has agreed to expand the Board of Directors from four to five members immediately and to six directors at the 2015 Annual Meeting of Stockholders. The Board appointed Bradley J. Sacks to fill the initial vacancy on the company's Board of Directors. Mr. Sacks is an investor and advisor, and has been since 2009 the managing member of Centric Capital Ventures LLC. In addition, the Board of Directors will be recommending the appointment of Robert F. Goldrich to fill the sixth seat on the board at the 2015 Annual Meeting of Stockholders.

ULURU Inc. Announces Interim Pharmacoeconomic Data

ULURU Inc. announced interim results of a pharmacoeconomic evaluation being conducted in Europe. The pharmacoeconomic data has two components. The first component is the costs associated with using Altrazeal compared to both a conventional dry wound healing dressings and advanced moist wound dressings for an identical duration of treatment. The second component compares the cost of using Altrazeal to conventional dry wound healing dressings and advanced moist wound dressings for the duration of treatment through wound closure. Currently, the CE Mark in Europe allows for Altrazeal to remain in place for up to 14 days. Clinical practice in this patient population resulted in Altrazeal being changed on average every 9 days. Despite the unit cost of Altrazeal being higher than competitive dressings, the reduction in dressing changes and the associated personnel costs makes Altrazeal markedly economically preferable to conventional gauze dressings and advanced moist wound dressings including hydrocolloids, alginates, and foam dressings. The interim data comparing Altrazeal with conventional dry wound healing and advanced moist wound dressings on similar wounds for the duration of treatment through wound closure includes 43 patients treated with Altrazeal. In the patient population evaluated, compared to patients in available data bases using conventional treatments, Altrazeal demonstrated acceleration in wound healing. When combined with the lower treatment cost associated with using Altrazeal, this generates a significant reduction in the cost to complete wound closure. The cost comparison using Altrazeal under the assumption of an identical 50 day period compared with alternative approaches.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ULUR:US $0.34 USD +0.0101

ULUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $139.84 USD -1.90
Smith & Nephew PLC 1,150 GBp -16.00
View Industry Companies
 

Industry Analysis

ULUR

Industry Average

Valuation ULUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.4x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ULURU INC, please visit www.uluruinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.